Skip to main content
    G

    Gossamer Bio Inc (GOSS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.98
    +0.01 (+0.09%)

    Market Cap: $67.10M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Gossamer Bio Inc (GOSS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Gossamer Bio reported revenue of $48.47M for the fiscal year ended Dec 31, 2025, down 57.7% from the year before. That year, net income was -$170.37M with a net margin of -351.5%, operating cash flow was -$171.27M and free cash flow was -$171.34M. The quarter ended Sep 30, 2026 had revenue of $38.43M and net income of -$48.07M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$48.47M-57.7%100.0%-352.2%-351.5%
    Dec 2024$114.70MN/A100.0%-52.2%-49.3%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$48.47M$114.70M$0$0$0$0$0$0$0$0
    Gross profit$48.47M$114.70M$0$0$0$0$0$0$0$0
    Research and development$181.57M$138.49M$145.30M$170.92M$170.27M$184.23M$147.00M$104.94M$6.39M$0
    Operating income-$170.73M-$59.92M-$183.76M-$218.59M-$216.12M-$233.96M-$186.14M-$148.99M-$6.65M-$83.00K
    Net income-$170.37M-$56.53M-$179.82M-$229.38M-$234.00M-$243.36M-$180.31M-$146.97M-$6.77M-$83.00K
    EBITDA-$166.73M-$53.72M-$172.05M-$212.89M-$203.09M-$225.91M-$182.97M-$148.38M-$6.65M-$83.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$38.43M$9.24M$16.95M$13.80M$13.29M$11.49M$9.89M$9.38M$9.48M$95.84M$0$6.78M
    Gross profit$38.43M$9.24M$16.95M$13.80M$13.29M$11.49M$9.89M$9.38M$9.48M$95.84M$0$5.78M
    Operating income$7.20M-$26.07M-$44.87M-$46.04M-$49.11M-$38.77M-$36.81M-$36.13M-$33.92M$52.09M-$41.96M-$49.03M
    Net income-$48.07M$16.90M-$46.66M-$47.24M-$48.22M-$38.27M-$36.64M-$33.03M-$30.80M$49.23M-$41.93M-$48.15M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $198.51M exceeded cash and equivalents by $160.78M. Shareholder equity was negative, at -$122.76M, as total liabilities of $295.01M exceeded total assets of $172.25M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$172.25M$315.29M$311.92M$272.45M$343.66M$539.43M$426.60M$239.42M$445.00K$60.00K
    Current assets$167.64M$309.89M$306.52M$261.88M$331.78M$522.32M$409.32M$231.95M$445.00K$60.00K
    Cash and equivalents$37.73M$46.07M$32.11M$111.97M$183.40M$486.06M$135.03M$105.22M$315.00K$60.00K
    Total liabilities$295.01M$285.80M$249.15M$260.37M$222.19M$218.75M$74.12M$21.12M$7.31M$183.00K
    Short-term debt$0$961.00K$11.61M$11.61M$0$3.63M$2.35MN/AN/AN/A
    Long-term debt$198.51M$197.52M$197.41M$207.70M$179.12M$172.39M$28.46M$0$6.04M$40.00K
    Shareholder equity-$122.76M$29.49M$62.77M$12.08M$121.46M$320.68M$352.49M-$120.07M-$6.86M-$123.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$64.34M$76.87M$128.90M$172.25M$208.82M$240.93M$280.59M$315.29M$350.88M$373.45M$259.36M$311.92M
    Total liabilities$187.13M$170.90M$290.38M$295.01M$291.15M$287.03M$286.84M$285.80M$296.74M$291.92M$232.64M$249.15M
    Cash and equivalents$51.19M$41.15M$41.03M$37.73M$8.93M$26.31M$29.02M$46.07M$28.46M$86.88M$38.86M$32.11M
    Shareholder equity-$122.80M-$94.03M-$161.48M-$122.76M-$82.33M-$46.11M-$6.25M$29.49M$54.14M$81.53M$26.72M$62.77M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$171.27M-$3.47M-$159.16M-$187.03M-$188.89M-$176.36M-$144.83M-$51.04M-$5.75M$20.00K
    Capital expenditures$79.00K$0$0$410.00K$1.55M$1.50M$2.97M$3.49M$3.49M$3.49M
    Free cash flow-$171.34M-$3.47M-$159.16M-$187.44M-$190.44M-$177.86M-$147.80M-$54.53M-$9.23M-$3.47M
    Investing cash flow$156.36M$29.02M-$110.97M-$1.03M-$117.43M$215.34M-$147.14M-$144.71M-$144.71M-$144.71M
    Financing cash flow$6.42M-$11.49M$190.15M$117.09M$3.33M$312.54M$321.58M$300.86M$6.00M$40.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$29.58M-$39.42M-$38.72M-$48.31M-$36.17M-$47.06M-$39.72M-$35.48M-$32.03M$116.35M-$52.30M-$33.42M
    Capital expendituresN/AN/A$0$0$0$53.00K$26.00K$0$32.03M$116.35M$0$60.00K
    Free cash flowN/AN/A-$38.72M-$48.31M-$36.17M-$47.11M-$39.75M-$35.48M-$64.07M$0-$52.30M-$33.48M
    Last 12 quarters

    Frequently Asked Questions About GOSS

    What is Gossamer Bio's annual revenue?

    Gossamer Bio reported revenue of $48.47M for the fiscal year ended Dec 31, 2025.

    How fast is Gossamer Bio's revenue growing?

    Revenue was down 57.7% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Gossamer Bio profitable?

    No. Gossamer Bio reported net income of -$170.37M for the fiscal year ended Dec 31, 2025, with a net margin of -351.5%.

    How much free cash flow does GOSS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$171.27M minus capital expenditures of $79.00K produced free cash flow of -$171.34M.

    How much debt does Gossamer Bio have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $198.51M, short-term debt of $0 and cash and equivalents of $37.73M.